List of Excipients in Branded Drug CLOBETASOL PROPIONATE CREAM

Generic Drugs Containing CLOBETASOL PROPIONATE CREAM

Company	Ingredient	NDC	Excipient
Sola Pharmaceuticals	clobetasol propionate cream	70512-028	ANHYDROUS CITRIC ACID
Sola Pharmaceuticals	clobetasol propionate cream	70512-028	CETYL ALCOHOL
Sola Pharmaceuticals	clobetasol propionate cream	70512-028	GLYCOL STEARATE

What are the Most Frequently-Used Excipients in CLOBETASOL PROPIONATE CREAM?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	CETYL ALCOHOL
1	GLYCOL STEARATE

Clobetasol Propionate Cream Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Clobetasol propionate 0.05% cream is an established generic topical corticosteroid with limited active-ingredient exclusivity and substantial room for differentiation through formulation performance, tolerability, packaging, and channel strategy. The strongest commercial opportunities are low-irritancy vehicles, preservative-conscious formulations, improved spreadability, lower residue, lifecycle extensions into specialty dermatology, and contract manufacturing for private-label products.

What is the FDA and commercial status of clobetasol propionate cream?

Clobetasol propionate cream is a high-potency topical corticosteroid approved for short-term treatment of corticosteroid-responsive dermatoses, including inflammatory and pruritic skin conditions. The commonly marketed strength is 0.05% w/w.

Attribute	Commercial and regulatory position
Active ingredient	Clobetasol propionate
Dosage form	Topical cream
Typical strength	0.05%
Drug class	Very-high-potency topical corticosteroid
FDA pathway for generics	Abbreviated New Drug Application, or ANDA
Reference brand	Temovate cream and related historical branded products
Prescription status	Prescription-only
Typical treatment duration	Usually limited to short courses under labeling
Primary risks	Skin atrophy, HPA-axis suppression, systemic corticosteroid exposure, irritation and contact sensitization
Commercial status	Multiple approved generic products
Core active-ingredient exclusivity	Expired
Main competitive barriers	Formulation equivalence, topical bioequivalence, manufacturing consistency, pharmacy substitution and contracting

The FDA labeling limits the use of clobetasol propionate cream because of its potency and the risk of local and systemic adverse effects. Labeling commonly limits treatment to no more than two consecutive weeks and no more than 50 grams per week, although exact instructions depend on the approved product label and indication. The product is generally not intended for use on the face, groin, axillae, or other thin-skinned areas unless specifically directed by a physician. [1]

The commercial market is therefore less dependent on broad chronic-use volume than on repeat prescriptions for psoriasis, eczema, dermatitis, lichen planus and other localized inflammatory dermatoses.

What excipients are used in clobetasol propionate cream?

Clobetasol propionate cream formulations commonly contain an oil-in-water emulsion with a fatty alcohol, emulsifier, humectant or solvent, preservative system, water phase, and emollient components.

Representative excipient classes include:

Excipient class	Common examples	Primary function
Solvent or humectant	Propylene glycol, glycerin	Solubilization, moisturization, skin feel
Emollient	Mineral oil, isopropyl myristate, white petrolatum	Occlusivity, lubrication, barrier support
Emulsifier	Glyceryl stearate, polysorbate 60, PEG stearates	Emulsion stability
Consistency agent	Cetostearyl alcohol, stearyl alcohol, carbomer	Viscosity and spreadability
Preservative	Methylparaben, propylparaben, phenoxyethanol	Microbial protection
Buffer or chelator	Sodium citrate, citric acid, edetate salts	pH and stability control
Aqueous phase	Purified water	Continuous phase
Appearance modifier	Titanium dioxide or other approved opacifiers	Whiteness and product appearance

The exact composition differs among approved products. The FDA Inactive Ingredient Database and approved product labeling should be used to confirm whether a proposed excipient, concentration and route have precedent in topical semisolid products. [2,3]

A formulation should not be selected solely because each individual excipient has prior topical use. The combination can affect clobetasol solubility, particle state, release rate, skin permeation, preservative performance, viscosity and patient tolerability.

How should the excipient strategy be designed for clobetasol propionate cream?

The preferred strategy is to control drug thermodynamic activity while minimizing irritation and maintaining reproducible semisolid performance.

1. Control clobetasol solubilization

Clobetasol propionate has low aqueous solubility. The formulation must determine whether the drug is fully dissolved, partially dissolved, or present as a controlled suspension. This decision directly affects:

• In vitro release rate
• Skin permeation
• Dose uniformity
• Physical stability
• Risk of crystallization during storage
• Sensitivity to manufacturing temperature and shear

Propylene glycol is widely used in topical corticosteroid products because it can support solubilization and improve skin hydration. Its disadvantages include stinging, irritation and potential contact dermatitis, particularly on compromised skin.

A lower-irritancy solvent system may use a reduced propylene glycol concentration, glycerin, glycols with suitable topical precedent, or a mixed solvent system. The commercial tradeoff is that lower solvent strength can increase crystallization risk or reduce release unless the emulsion structure is redesigned.

2. Optimize the oil phase for skin feel

Mineral oil and petrolatum provide barrier support but can produce greasiness and residue. Isopropyl myristate and similar esters can improve spreadability and reduce the perception of heaviness, but they may alter penetration and can increase irritation or comedogenicity concerns in some users.

A commercial formulation can target one of three profiles:

Vehicle position	Design objective	Likely commercial use
Rich and occlusive	Maximum moisturization and barrier support	Lichenified lesions, dry plaques, night use
Balanced cream	Moderate residue with good spreadability	General prescription dermatology
Lightweight cream	Rapid absorption and low cosmetic burden	Daytime use, exposed areas and adherence-sensitive patients

For a high-potency corticosteroid, the lightweight option has commercial appeal but requires careful control of drug release and skin exposure. A lighter vehicle must not create unintentionally higher permeation or a more rapid systemic absorption profile.

3. Select emulsifiers and fatty alcohols for robustness

Glyceryl stearate, cetostearyl alcohol and stearyl alcohol are common structural excipients. They can improve viscosity, emulsion stability and skin feel. Their concentrations influence:

• Cream yield stress
• Spreadability
• Rub-in time
• Phase separation
• Temperature stability
• Patient perception of residue

Fatty alcohols can occasionally contribute to irritation or sensitization. A formulation intended for sensitive-skin positioning should evaluate the complete excipient system rather than focusing only on the active ingredient.

4. Address preservative and sensitization risk

Parabens, phenoxyethanol and other preservatives can provide effective microbial protection, but preservative choice is a potential product differentiator.

A "preservative-free" clobetasol cream may be commercially attractive, but it introduces manufacturing and packaging requirements. The product may require:

• An airless pump
• A unit-dose container
• A low-bioburden manufacturing process
• A validated antimicrobial protection strategy
• Demonstrated in-use microbiological control

A tube package is simple and familiar but exposes the formulation to repeated environmental contact. An airless pump can support a preservative-reduced positioning but increases packaging cost and may complicate filling, dose delivery and regulatory comparability.

5. Set a skin-compatible pH

The target pH should support drug stability, preservative efficacy and skin tolerability. Excessively acidic or alkaline conditions can increase stinging and destabilize the emulsion or preservative system.

A practical development window should be selected through stability and tolerability studies rather than copied from a competing product. Buffer capacity should remain low enough to avoid unnecessary interference with the skin surface.

What formulations are protected by clobetasol propionate cream patents?

The core clobetasol propionate composition is not commercially protected by an active foundational patent in the way a recently approved drug would be. The market has long included generic creams, ointments, gels, solutions and foams.

Potentially protectable subject matter can still include:

• A defined excipient ratio
• A narrow particle-size distribution
• A supersaturated or substantially dissolved drug state
• A controlled crystallization profile
• A low-irritancy solvent system
• A preservative-free multidose package
• A metered-dose delivery system
• A foam or aerosol vehicle
• A combination with a keratolytic or barrier-repair agent
• A manufacturing process that produces a defined microstructure
• A specific method of treating a disease or anatomical site

A formulation patent must provide more than a list of conventional excipients. The strongest claim position would link the composition to a measurable technical result, such as improved release, reduced crystallization, improved stability, lower irritation, improved dose uniformity or a clinically relevant adherence benefit.

The key patent risk is that many cream components are individually conventional. Broad claims covering clobetasol propionate, water, propylene glycol, fatty alcohols and an emulsifier would face substantial prior-art exposure. Narrower claims directed to composition ranges, microstructure, packaging or demonstrated performance are more defensible.

How does FDA approval work for a generic clobetasol propionate cream?

A generic sponsor normally files an ANDA referencing the applicable FDA-listed reference product. The sponsor must demonstrate pharmaceutical equivalence and bioequivalence under the FDA’s requirements for topical semisolid products.

The development package commonly includes:

1. Drug substance characterization.
2. Quantitative and qualitative excipient assessment.
3. Comparative product characterization.
4. Assay and content uniformity.
5. Rheology and viscosity.
6. Globule or particle-size distribution where relevant.
7. pH, density and water activity.
8. Microbial limits and preservative effectiveness.
9. In vitro release testing.
10. In vitro permeation or other product-specific comparative testing where required.
11. Stability data.
12. Container-closure compatibility.
13. Manufacturing process validation.

For a topical cream, Q1 sameness means the same ingredients, while Q2 sameness generally concerns the same concentrations. Q3 characterization evaluates physical and structural properties, including the attributes that determine drug release and delivery. FDA’s topical product guidance treats these attributes as central to product equivalence. [4]

A sponsor that intentionally changes the vehicle for commercial differentiation may need a new drug application, a 505(b)(2) pathway, or another regulatory strategy rather than a conventional ANDA, depending on the change and the proposed claims.

What commercial opportunities exist for clobetasol propionate cream?

Low-irritancy formulation

A reduced-propylene-glycol, fragrance-free, dye-free cream could target patients with sensitive or barrier-impaired skin. The commercial value depends on demonstrating lower stinging or better tolerability without compromising bioequivalence and stability.

Preservative-conscious packaging

A preservative-reduced or preservative-free product in an airless pump could command a premium in dermatology channels. The opportunity is strongest where prescribers or patients are concerned about excipient sensitivity. Packaging cost and reimbursement limits may constrain uptake.

Improved cosmetic acceptability

A fast-spreading, lower-residue cream may improve adherence in daytime use. Product attributes that can support differentiation include:

• Shorter rub-in time
• Reduced greasiness
• Lower transfer to clothing
• Consistent dispensing
• No visible grittiness
• Stable appearance over shelf life

These claims require substantiation and must remain consistent with the approved label and promotional rules.

Specialty dermatology and private label

Dermatology-focused manufacturers, specialty pharmacies and teledermatology platforms may use clobetasol cream as part of a broader topical portfolio. A contract development and manufacturing organization could offer:

• Custom vehicle selection
• Small-batch clinical supplies
• Private-label prescription products
• Tube and pump filling
• Dermatology packaging
• Stability and regulatory support

The active ingredient is inexpensive. Value is created through reliable supply, low minimum order quantities, packaging flexibility and formulation know-how.

Combination and adjunctive products

Combination opportunities include clobetasol with moisturization or barrier-support concepts. A direct combination containing another active ingredient creates greater regulatory and patent complexity. A separate emollient product marketed for use alongside clobetasol may be easier to commercialize but cannot make unsupported combination-treatment claims.

Geographic expansion

Clobetasol propionate is marketed internationally in several topical dosage forms. Geographic opportunities depend on:

• Local prescription status
• National reference-product requirements
• Accepted bioequivalence standards
• Excipient restrictions
• Language and labeling requirements
• Reimbursement and tender systems
• Local manufacturing or import rules

The United States rewards ANDA-scale manufacturing and payer access. European markets may place greater emphasis on national authorization, decentralized procedures and local reimbursement. Emerging markets may favor low-cost tubes and government tenders over premium packaging.

Which companies compete in clobetasol propionate cream?

Competition includes generic dermatology manufacturers, contract manufacturers and companies with established topical portfolios. The market can include products from firms such as Taro, Perrigo, Glenmark, Fougera, Padagis, Encube and other ANDA holders or private-label suppliers, depending on current product availability and distribution arrangements.

Competitive analysis should compare:

Commercial factor	Why it matters
Approved dosage forms	Cream, ointment, gel, solution, lotion and foam address different use cases
Tube size	Common sizes include 15 g, 30 g and 60 g, subject to product labeling
Wholesale acquisition cost	Determines payer and pharmacy positioning
Generic sourcing	Affects pharmacy continuity and supply reliability
Formulation reputation	Influences prescriber and patient preference
Packaging	Tube, pump and unit-dose formats support different positions
Manufacturing location	Affects supply risk and procurement requirements
Regulatory record	Inspection history and supplement execution affect continuity
Channel access	Retail, specialty pharmacy, dermatology clinics and digital health

Exact market share and revenue exposure require current IQVIA, FDA, wholesaler and company data. Public labels generally do not disclose unit volume or net sales.

What is the Orange Book and patent status of clobetasol propionate cream?

The Orange Book identifies approved drug products, reference-listed drugs, therapeutic-equivalence information and certain patent or exclusivity information. For an old generic topical product, the principal commercial issue is usually not active-ingredient patent expiry. It is whether a new formulation or delivery system creates a separate, enforceable patent position.

A sponsor evaluating clobetasol propionate cream should review:

• Current Orange Book listings for the reference product.
• Approved ANDA products and therapeutic-equivalence codes.
• Listed patents for any branded formulation or delivery system.
• FDA exclusivity entries.
• USPTO patent families covering topical vehicles.
• Patent litigation involving a proposed differentiated product.
• Paragraph IV certifications for any later-listed formulation patents.

A Paragraph IV challenge is relevant only where an ANDA applicant seeks approval before expiry of a listed patent and certifies that the patent is invalid, unenforceable or will not be infringed. Because conventional clobetasol cream is an old generic category, Paragraph IV risk is more likely to concern a newer formulation, foam, device or combination product than a basic cream vehicle.

What litigation and settlement risks affect clobetasol cream?

Litigation risk is generally low for a conventional clobetasol propionate cream with expired active-ingredient protection. Risk increases when a product claims:

• A proprietary emulsion structure
• A new delivery device
• A novel combination
• A specific particle or crystal form
• Improved penetration or reduced systemic exposure
• A branded clinical use protected by method-of-use patents

Settlement agreements involving generic entry, authorized generics or formulation patents should be reviewed through FDA, FTC and court records. A formulation sponsor should avoid relying on a patent strategy based only on conventional excipient substitution. The commercial case must be supported by measurable product performance and a clear regulatory pathway.

How strong is the patent estate for a differentiated clobetasol cream?

Patent subject matter	Relative strength
Broad clobetasol cream composition	Weak because of extensive prior art
Conventional propylene glycol emulsion	Weak
Defined low-irritancy excipient range	Moderate if supported by comparative data
Preservative-free package and formulation	Moderate
Novel microstructure with release advantage	Moderate to strong if reproducible
Metered-dose delivery system	Moderate, depending on device prior art
Combination with a new active ingredient	Potentially strong but complex
Specific manufacturing process	Moderate if process parameters create a required product attribute
Method-of-use claim for an established indication	Often vulnerable unless narrow and clinically differentiated

The strongest practical protection is usually a coordinated portfolio covering composition, manufacturing process, packaging and method of use. Regulatory exclusivity may be limited, so patent scope and enforceability must carry the commercial strategy.

What generic launch scenarios exist for clobetasol propionate cream?

Conventional ANDA launch

This is the lowest-cost route and supports pharmacy substitution. It also produces the greatest price competition and the weakest differentiation.

Premium generic launch

A sponsor can use a better-tolerated vehicle, cleaner packaging or improved cosmetic properties. The product still faces ANDA constraints if it must match the reference product closely.

505(b)(2) formulation launch

A materially different cream, gel, foam, device or combination may support a 505(b)(2) strategy. The development burden and clinical requirements are higher, but the sponsor may obtain formulation or method-of-use exclusivity.

Private-label dermatology launch

A manufacturer can supply a dermatology group, specialty pharmacy or digital health provider. This model depends on reliable supply, compliant promotion and payer acceptance.

Regional licensing

A company with a distinctive vehicle or packaging platform can license the technology to a regional generic manufacturer. Licensing value depends on patent term, regulatory transferability, manufacturing scale and local reimbursement.

Key Takeaways

• Clobetasol propionate 0.05% cream is an established generic product with expired core active-ingredient exclusivity.
• Excipient selection affects solubility, release, permeation, stability, irritation and patient adherence.
• Propylene glycol, fatty alcohols, glyceryl stearate, mineral oil, petrolatum and preservatives are common formulation tools, but exact compositions vary by approved product.
• The most credible commercial differentiation is a low-irritancy, low-residue, preservative-conscious or packaging-enabled cream.
• Conventional excipient substitutions have limited patent strength unless linked to defined performance advantages.
• A materially different formulation may require a 505(b)(2) strategy rather than a standard ANDA.
• The principal commercial risks are price erosion, pharmacy substitution, supply reliability, regulatory comparability and weak patent breadth.
• A premium strategy should be supported by comparative release, stability, tolerability, package-performance and adherence data.

FAQs About Clobetasol Propionate Cream Excipient Strategy

Can propylene glycol be removed from clobetasol propionate cream?

Yes, but removing it can change drug solubility, crystallization, release and skin permeation. A replacement system must be evaluated through comparative formulation, stability and topical performance testing.

Is a preservative-free clobetasol cream commercially viable?

Yes, particularly with an airless pump or unit-dose package. The additional packaging cost and microbial-control requirements may limit the product to specialty or premium channels.

Can a new excipient combination receive a patent?

Potentially. Patentability is stronger when the combination produces an unexpected and measurable benefit, such as improved release, lower irritation, reduced crystallization or enhanced stability.

Does a lighter clobetasol cream reduce corticosteroid safety risk?

Not necessarily. A lighter sensory profile does not establish lower systemic exposure or lower local potency. Safety depends on dose, duration, application site, skin condition and product delivery.

Is clobetasol propionate cream suitable for a cosmetic over-the-counter product?

No. Clobetasol is a high-potency prescription corticosteroid. An over-the-counter cosmetic product cannot lawfully make drug claims or contain clobetasol as an unapproved active ingredient.

References

1. U.S. Food and Drug Administration. (2023). Clobetasol propionate cream, 0.05% prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. National Library of Medicine. (2024). DailyMed: Clobetasol propionate topical products. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (2022). Topical dermatologic drug products approved under an ANDA: Product-specific guidance and bioequivalence recommendations. FDA.